30岁以下股骨头坏死患者全髋关节置换术:平均随访超过120个月
这项回顾性单中心研究评估了66例股骨头坏死患者(99髋)初次全髋关节置换术后的长期假体存活率和临床结局,按手术时年龄分为30岁以下组(20髋)和30岁及以上组(79髋),平均随访128.1个月。末次随访时两组日本骨科协会评分中位数均为100分(P=0.41),总体假体存活率60个月为100%、120个月为98%、180个月为94%,以无菌性松动为终点时180个月存活率为100%,两组间无显著差异。作者认为全髋关节置换术对年轻股骨头坏死患者是安全有效的治疗,超过120个月仍显示疗效。
要点
- 30岁以下组与30岁及以上组末次随访日本骨科协会评分中位数均为100分(P=0.41)。
- 总体假体存活率60个月100%、120个月98%、180个月94%。
- 以无菌性松动为终点时180个月存活率为100%,两组间无显著差异。
核心结论
- 全髋关节置换术对年轻股骨头坏死患者是安全有效的治疗,超过120个月仍显示疗效。
- 假体与翻修技术的进步支持全髋关节置换术作为年轻股骨头坏死患者的可行治疗,甚至可作为初始治疗。
- 未来研究应评估更长随访时间、更大队列和标准化手术方法。
研究设计与样本
- 回顾性单中心研究,评估1997年至2019年间接受初次全髋关节置换术的66例股骨头坏死患者共99髋。
- 按全髋关节置换术时年龄分为A组(小于30岁,20髋)和B组(30岁及以上,79髋)。
- 平均年龄43岁,36例为男性,平均随访时间128.1个月。
- 比较临床和影像学特征。
主要发现
- 末次随访时日本骨科协会评分中位数两组均为100分(P=0.41)。
- 主要并发症发生于13髋:A组1髋,B组12髋(P=0.46)。
- 总体假体存活率60个月为100%、120个月为98%、180个月为94%。
- 以无菌性松动为终点时,180个月存活率为100%。
- 以任一终点评估,两组间存活率均无显著差异(P=1.00,P=0.67)。
关键数值与推荐
- 日本骨科协会评分中位数:A组100分 vs B组100分(P=0.41)。
- 主要并发症:A组1髋 vs B组12髋(P=0.46)。
- 总体假体存活率:60个月100%、120个月98%、180个月94%。
- 以无菌性松动为终点:180个月存活率100%。
- 两组存活率比较:P=1.00(终点一)、P=0.67(终点二),均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究应评估更长随访时间、更大队列和标准化手术方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteonecrosis of the femoral head (ONFH) primarily affects young adults, leading to femoral head collapse and secondary osteoarthritis. Treatments include joint-preserving surgery, which has been performed preferentially, especially for young adults, and joint arthroplasty, i.e., total hip arthroplasty (THA). Although advancements in implant materials have markedly improved performance, there are few data regarding implant survival and clinical outcomes in younger patients. This study aimed to assess long-term implant survival of more than 120 months and clinical outcomes in young ONFH patients undergoing primary THA. METHODS: This retrospective single-center study assessed 99 joints in 66 ONFH patients who underwent primary THA between 1997 and 2019. Patients were categorized according to age at the time of THA: group A, aged less than 30 years (20 joints) and group B, aged 30 years or more (79 joints). The mean age was 43 years, and 36 patients were men. The mean follow-up duration was 128.1 months. Clinical and radiographic characteristics were compared. RESULTS: The median Japanese Orthopaedic Association score at the final follow-up was 100 in both groups (P = 0.41). Major complications occurred in 13 joints: one in group A and 12 in group B (P = 0.46). Overall implant survival rate was 100% at 60 months, 98% at 120 months, and 94% at 180 months. When considering aseptic loosening as the endpoint, the 180-month survival rate was 100%. No significant differences in survival rate were found between the groups with either endpoint (P = 1.00, P = 0.67). CONCLUSIONS: Our results showed THA was a safe, effective treatment for young ONFH patients, with demonstrated efficacy over 120 months. Advances in implants and revision techniques support THA as a viable treatment, even as an initial treatment for young ONFH patients. Future research should assess longer follow-up with larger cohorts and standardized surgical methods.
引用
- Kuniyoshi S, Nakasone S, Takaesu M, et al. Total Hip Arthroplasty in Patients Under 30 Years Who Have Osteonecrosis of the Femoral Head: Mean Follow-Up of More than 120 Months. J Arthroplasty. 2025. PMID: 40473057. doi:10.1016/j.arth.2025.05.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。